The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Pharma giant targets new standards of care
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
At the core of Verida is Spectral Precise Image technology paired with a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Subscribe To Our Newsletter & Stay Updated
